Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cerilliant
Harvard Business School
Medtronic
Express Scripts
Mallinckrodt
UBS
Johnson and Johnson
McKinsey
Covington

Generated: October 24, 2017

DrugPatentWatch Database Preview

Regadenoson - Generic Drug Details

« Back to Dashboard

What are the generic sources for regadenoson and what is the scope of regadenoson patent protection?

Regadenoson
is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Regadenoson has eighty-three patent family members in twenty-six countries and eleven supplementary protection certificates in ten countries.

There are seven drug master file entries for regadenoson. One supplier is listed for this compound.

Summary for Generic Name: regadenoson

US Patents:17
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list7
Suppliers / Packagers: see list1
Bulk Api Vendors: see list25
Clinical Trials: see list50
Patent Applications: see list76
Drug Prices:see low prices
DailyMed Link:regadenoson at DailyMed

Pharmacology for Ingredient: regadenoson

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: regadenoson

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,988Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
8,071,566Methods of coronary imaging► Subscribe
8,278,435N-pyrazole A2A receptor agonists► Subscribe
7,732,595Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs► Subscribe
8,524,883Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide► Subscribe
7,956,179Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
9,163,057Methods of myocardial perfusion imaging► Subscribe
8,906,878Myocardial perfusion imaging methods and compositions► Subscribe
8,569,260N-pyrazole A.sub.2A receptor agonists► Subscribe
7,671,192Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: regadenoson

Country Document Number Estimated Expiration
South Africa200500855► Subscribe
China102260311► Subscribe
Israel182645► Subscribe
Israel147198► Subscribe
Canada2583185► Subscribe
Russian Federation2007114908► Subscribe
Russian Federation2447081► Subscribe
South Africa200200301► Subscribe
China1167709► Subscribe
New Zealand570239► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: REGADENOSON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2Finland► Subscribe
2011Austria► SubscribePRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
00477Netherlands► SubscribePRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2011000010Germany► SubscribePRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
C004/2011Ireland► SubscribeSPC004/2011: 20110719, EXPIRES: 20250620
2/2011Austria► SubscribePRODUCT NAME: REGADENOSON UND DESSEN SALZE
C/GB11/005United Kingdom► SubscribePRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
785Luxembourg► Subscribe91785, EXPIRES: 20250621
90003-2.LSweden► SubscribePRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
2011 00005Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Johnson and Johnson
Cerilliant
Queensland Health
Deloitte
Moodys
US Army
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot